Since April 2012, and as of 5 February 2024, a total of 2 617 cases of MERS-CoV, including 947 deaths, have been reported by health authorities worldwide.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 4-10 February 2024 and includes updates on avian influenza, measles, MERS-CoV, COVID-19, swine influenza, respiratory virus epidemiology, Western equine encephalitis, Hepatitis E, and the Chinese New Year.
The food-borne infections listeriosis and shigatoxigenic Escherichia coli are increasing in the EU/EEA and were in 2022 at levels higher than before the COVID-19 pandemic.
In 2022, 30 EU/EEA countries reported 4 548 cases of hepatitis A. The EU/EEA notification rate was one case per 100 000 population. Twenty EU/EEA countries had notification rates below one case per 100 000 population. The countries with the highest notification rates were Hungary (5.5), Croatia (5.3) Romania (4.8), and Bulgaria (4.4).
This core protocol for ECDC studies of VE against hospitalisation with SARI laboratory-confirmed with SARS-CoV-2 or with influenza, version 3.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with SARI, initially published as version 1.0 [5], updated to version 2.0 [6].
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 28 January - 3 February 2024 and includes updates on SARS-CoV-2 variant classification, swine influenza, human cases of co-infection with seasonal influenza and avian influenza, influenza, western equine encephalitis, and an overview of respiratory virus epidemiology in the EU/EEA.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 21-27 January 2024 and includes updates on SARS-CoV-2, influenza, cholera, chikungunya, dengue and zika.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 14-20 January 2024 and includes updates on avian influenza, SARS-CoV-2 variant classification, an overview of respiratory viruses in the EU/EEA, mpox, measles, and Infant formula for medical purposes recalled due to possible contamination with Cronobacter sakazakii.